Published in J Virol on July 01, 1998
An alternative approach to medical genetics based on modern evolutionary biology. Part 4: HERVs in cancer. J R Soc Med (2009) 0.82
Evolutionary impact of transposable elements on genomic diversity and lineage-specific innovation in vertebrates. Chromosome Res (2015) 0.80
Human endogenous retrovirus group E and its involvement in diseases. Viruses (2015) 0.78
Midkine and Pleiotrophin Concentrations in Amniotic Fluid in Healthy and Complicated Pregnancies. PLoS One (2016) 0.76
Structure, variation and synthesis of retrovirus long terminal repeat. Cell (1981) 4.90
The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci U S A (1996) 4.48
Identification of human endogenous retroviruses with complex mRNA expression and particle formation. Proc Natl Acad Sci U S A (1993) 2.43
Nucleotide sequence of a full-length human endogenous retroviral segment. J Virol (1985) 2.36
Mammalian tRNA genes: nucleotide sequence of rat genes for tRNAAsp, tRNAGly and tRNAGlu. Nucleic Acids Res (1981) 2.06
Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science (1990) 2.00
Nucleotide sequence of the haptoglobin and haptoglobin-related gene pair. The haptoglobin-related gene contains a retrovirus-like element. J Biol Chem (1985) 2.00
mRNA transcripts related to full-length endogenous retroviral DNA in human cells. Nature (1984) 1.94
Endogenous retroviral sequences are required for tissue-specific expression of a human salivary amylase gene. Genes Dev (1992) 1.92
Retroviral and pseudogene insertion sites reveal the lineage of human salivary and pancreatic amylase genes from a single gene during primate evolution. Mol Cell Biol (1990) 1.79
Nucleotide sequences of the retroviral long terminal repeats and their adjacent regions. Nucleic Acids Res (1984) 1.72
Distinctive termini characterize two families of human endogenous retroviral sequences. Science (1984) 1.69
Evolutionary implications of primate endogenous retroviruses. Virology (1991) 1.62
Retroviral integrase, putting the pieces together. J Biol Chem (1996) 1.58
An 18-kd heparin-binding protein of developing brain that is distinct from fibroblast growth factors. EMBO J (1989) 1.57
Abundance of an endogenous retroviral envelope protein in placental trophoblasts suggests a biological function. Virology (1995) 1.56
Isolation and characterisation of the NBR2 gene which lies head to head with the human BRCA1 gene. Hum Mol Genet (1997) 1.50
Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus. Proc Natl Acad Sci U S A (1996) 1.42
Detection and cloning of murine leukemia virus-related sequences from African green monkey liver DNA. J Virol (1981) 1.38
Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem (1992) 1.37
Our retroviral heritage. Trends Genet (1997) 1.34
Human endogenous retrovirus type I-related viruses have an apparently widespread distribution within vertebrates. J Virol (1997) 1.27
Molecular cloning of the 18-kDa growth-associated protein of developing brain. J Biol Chem (1990) 1.22
Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice. Proc Natl Acad Sci U S A (1993) 1.22
Cellular distribution of the new growth factor pleiotrophin (HB-GAM) mRNA in developing and adult rat tissues. Anat Embryol (Berl) (1992) 1.16
Expression of human endogenous retrovirus K elements in germ cell and trophoblastic tumors. Am J Pathol (1996) 1.15
Splicing of a human endogenous retrovirus to a novel phospholipase A2 related gene. Nucleic Acids Res (1993) 1.13
The 5' end of the BRCA1 gene lies within a duplicated region of human chromosome 17q21. Oncogene (1996) 1.11
Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci U S A (1996) 1.10
A heparin-binding growth factor secreted from breast cancer cells homologous to a developmentally regulated cytokine. J Biol Chem (1992) 1.08
Autonomous expression of RTVL-H endogenous retroviruslike elements in human cells. J Virol (1990) 1.06
Mitogenic properties of a new endothelial cell growth factor related to pleiotrophin. Biochem Biophys Res Commun (1991) 1.04
Expression of type C-related endogenous retroviral sequences in human colon tumors and colon cancer cell lines. Proc Natl Acad Sci U S A (1986) 1.03
Three independent insertions of retrovirus-like sequences in the haptoglobin gene cluster of primates. Genomics (1990) 1.02
Mitogenic and in vitro angiogenic activity of human recombinant heparin affin regulatory peptide. Growth Factors (1994) 1.01
Characterization and genomic mapping of the ZNF80 locus: expression of this zinc-finger gene is driven by a solitary LTR of ERV9 endogenous retroviral family. Nucleic Acids Res (1995) 1.00
Midkine is a heat and acid stable polypeptide capable of enhancing plasminogen activator activity and neurite outgrowth extension. Biochem Biophys Res Commun (1995) 0.94
Expression of the HBNF (heparin-binding neurite-promoting factor) gene in the brain of fetal, neonatal and adult rat: an in situ hybridization study. Brain Res Dev Brain Res (1992) 0.89
Members of the RTVL-H family of human endogenous retrovirus-like elements are expressed in placenta. Gene (1989) 0.88
Subtractive cloning of a hybrid human endogenous retrovirus and calbindin gene in the prostate cell line PC3. Cancer Res (1991) 0.88
Transcription of human endogenous retroviral long terminal repeat (LTR) sequence in a lung cancer cell line. Biochem Biophys Res Commun (1990) 0.85
A tetracycline-responsive promoter system reveals the role of a secreted binding protein for FGFs during the early phase of tumor growth. Biochem Biophys Res Commun (1996) 0.79
Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer (2000) 5.24
A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nat Med (1997) 2.33
Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem (2001) 1.71
Human trophoblast and choriocarcinoma expression of the growth factor pleiotrophin attributable to germ-line insertion of an endogenous retrovirus. Proc Natl Acad Sci U S A (1996) 1.42
Ribozyme targeting demonstrates that the nuclear receptor coactivator AIB1 is a rate-limiting factor for estrogen-dependent growth of human MCF-7 breast cancer cells. J Biol Chem (2001) 1.38
Pleiotrophin stimulates fibroblasts and endothelial and epithelial cells and is expressed in human cancer. J Biol Chem (1992) 1.37
Expression of the nuclear coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Res Treat (2001) 1.34
Enhancement of fibroblast growth factor (FGF) activity by an FGF-binding protein. J Biol Chem (2001) 1.21
Chlorpheniramine plasma concentration and histamine H1-receptor occupancy. Clin Pharmacol Ther (1995) 1.15
Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril. J Cardiovasc Pharmacol (1987) 1.15
Receptor binding of propranolol is the missing link between plasma concentration kinetics and the effect-time course in man. Eur J Clin Pharmacol (1985) 1.15
Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res (1993) 1.14
Ribozyme-targeting elucidates a direct role of pleiotrophin in tumor growth. J Biol Chem (1994) 1.11
Melanoma angiogenesis and metastasis modulated by ribozyme targeting of the secreted growth factor pleiotrophin. Proc Natl Acad Sci U S A (1996) 1.10
Induction of the angiogenic modulator fibroblast growth factor-binding protein by epidermal growth factor is mediated through both MEK/ERK and p38 signal transduction pathways. J Biol Chem (2000) 1.10
An isoform of the coactivator AIB1 that increases hormone and growth factor sensitivity is overexpressed in breast cancer. J Biol Chem (2001) 1.07
Differentiation of beta 1- and beta 2-adrenoceptor-mediated effects in humans. Am J Physiol (1988) 1.04
Tumor growth and angiogenesis induced by a secreted binding protein for fibroblast growth factors. J Biol Chem (1994) 1.02
Pleiotrophin and midkine in normal development and tumor biology. Crit Rev Oncog (1995) 1.01
Inhibition of angiotensin-I response by cilazapril and its time course in normal volunteers. Clin Pharmacol Ther (1987) 1.00
Agonist binding at alpha 2-adrenoceptors of human platelets using 3H-UK-14,304: regulation by Gpp(NH)p and cations. Naunyn Schmiedebergs Arch Pharmacol (1987) 0.99
Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. Br J Cancer (2002) 0.99
Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst (1992) 0.98
Influence of the human endogenous retrovirus-like element HERV-E.PTN on the expression of growth factor pleiotrophin: a critical role of a retroviral Sp1-binding site. Oncogene (2000) 0.96
Pleiotrophin can be rate-limiting for pancreatic cancer cell growth. Cancer Res (2000) 0.94
Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. J Natl Cancer Inst (1998) 0.93
Distribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors. Mol Pharmacol (1991) 0.93
An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer (2001) 0.92
The potential role of the heparin-binding growth factor pleiotrophin in breast cancer. Breast Cancer Res Treat (1994) 0.91
Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase. Oncogene (2006) 0.91
Up-regulation of a fibroblast growth factor binding protein in children with renal diseases. Kidney Int (2001) 0.90
Signal transduction pathways involved in the mitogenic activity of pleiotrophin. Implication of mitogen-activated protein kinase and phosphoinositide 3-kinase pathways. J Biol Chem (1997) 0.89
Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor. Oncogene (2009) 0.88
Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex. Br J Clin Pharmacol (1988) 0.87
Expression of a binding protein for FGF is associated with epithelial development and skin carcinogenesis. Oncogene (1997) 0.87
The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat (1996) 0.87
Receptor binding characteristics and pharmacokinetic properties as a tool for the prediction of clinical effects of beta-blockers. Arzneimittelforschung (1985) 0.86
Affinity and selectivity of beta-adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol (1986) 0.85
Gene expression analysis in sections and tissue microarrays of archival tissues by mRNA in situ hybridization. Histol Histopathol (2005) 0.84
Transdermal delivery of bupranolol: pharmacodynamics and beta-adrenoceptor occupancy. Eur J Clin Pharmacol (1986) 0.84
d-sotalol reduces heart rate in vivo through a beta-adrenergic receptor-independent mechanism. Clin Pharmacol Ther (1993) 0.83
The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril. Br J Clin Pharmacol (1989) 0.83
Properties of agonist binding at the beta-adrenoceptor of the rat reticulocyte. Naunyn Schmiedebergs Arch Pharmacol (1982) 0.83
Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer. Int J Colorectal Dis (2012) 0.83
Mitogen-induced expression of the fibroblast growth factor-binding protein is transcriptionally repressed through a non-canonical E-box element. J Biol Chem (2000) 0.83
HER-2/neu is rate-limiting for ovarian cancer growth. Conditional depletion of HER-2/neu by ribozyme targeting. J Biol Chem (1997) 0.83
Concentration kinetics of propranolol, bisoprolol, and atenolol in humans assessed with chemical detection and a subtype-selective beta-adrenoceptor assay. J Cardiovasc Pharmacol (1986) 0.83
Phase I trial of pentosan polysulfate. Invest New Drugs (1995) 0.82
Dose-response curves of pirenzepine in man in relation to M1- and M2-cholinoceptor occupancy. Naunyn Schmiedebergs Arch Pharmacol (1988) 0.81
Serum induction of the fibroblast growth factor-binding protein (FGF-BP) is mediated through ERK and p38 MAP kinase activation and C/EBP-regulated transcription. Oncogene (2001) 0.81
Phase I trial of orally administered pentosan polysulfate in patients with advanced cancer. Clin Cancer Res (1997) 0.81
Comparison of biological phenotypes according to midkine expression in gastric cancer cells and their autocrine activities could be modulated by pentosan polysulfate. Cancer Lett (1997) 0.81
Phorbol ester-induced transcription of a fibroblast growth factor-binding protein is modulated by a complex interplay of positive and negative regulatory promoter elements. J Biol Chem (1998) 0.80
Differential regulation of extracellular signal-regulated kinase 1 and 2 activity during 12-O-tetradecanoylphorbol 13-acetate-induced differentiation of HL-60 cells. Exp Cell Res (1997) 0.80
Structure of the human heparin-binding growth factor gene pleiotrophin. Biochem Biophys Res Commun (1992) 0.80
Comparison of chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter by the androgen and glucocorticoid receptor. Exp Cell Res (1999) 0.80
A tetracycline-responsive promoter system reveals the role of a secreted binding protein for FGFs during the early phase of tumor growth. Biochem Biophys Res Commun (1996) 0.79
An additional 5'-upstream exon exists in the human pleiotrophin-encoding gene. Gene (1995) 0.79
Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1. J Invest Dermatol (1999) 0.78
DNA binding of the transcription factor PO-B is regulated during differentiation of HL-60 cells. Cell Growth Differ (1993) 0.78
Energy-dependent extrusion of cyclic 3',5'-adenosine-monophosphate. A drug-sensitive regulatory mechanism for the intracellular nucleotide concentration in rat erythrocytes. Naunyn Schmiedebergs Arch Pharmacol (1982) 0.78
In vivo inhibition of angiogenesis and induction of apoptosis by retinoic acid in squamous cell carcinoma. Clin Cancer Res (1997) 0.78
Study to confirm the lack of severe cardiac side-effects following treatment with the beta-adrenergic drug fenoterol. Gynecol Obstet Invest (1978) 0.77
Tissue distribution and retinoid-mediated downregulation of an FGF-binding protein (FGF-BP) in the rat. Growth Factors (2000) 0.77
Desensitization of the beta-adrenoceptor-adenylate cyclase system of immature erythrocytes by in-vivo treatment of rats with isoprenaline. Naunyn Schmiedebergs Arch Pharmacol (1981) 0.77
Simple and reliable radioreceptor assay for beta-adrenoceptor antagonists and active metabolites in native human plasma. Eur J Clin Pharmacol (1984) 0.77
Differential regulation of a fibroblast growth factor-binding protein by receptor-selective analogs of retinoic acid. Biochem Pharmacol (2000) 0.77
The bacterial polysaccharide tecogalan blocks growth of breast cancer cells in vivo. Oncol Rep (2001) 0.77
Ethnic differences in response to beta-blockade: fact or artefact? A study with bisoprolol and propranolol. Eur J Clin Pharmacol (1988) 0.77
Theory of ligand-receptor interactions--evidence for more than one site. Basic Res Cardiol (1984) 0.77
Purification and characterization of a novel growth factor from human breast cancer cells. Biochemistry (1992) 0.77
Regulation of gene expression of a binding protein for fibroblast growth factors by retinoic acid. J Biol Chem (1996) 0.76
Molecular and pharmacologic targeting of angiogenesis factors--the example of pleiotrophin. Breast Cancer Res Treat (1995) 0.76
Selective antagonists reveal different functions of M cholinoceptor subtypes in humans. Trends Pharmacol Sci (1989) 0.76
Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Ther (1997) 0.76
Ribozyme targeting of the growth factor pleiotrophin in established tumors: a gene therapy approach. Gene Ther (2005) 0.76
Radioreceptor assay of metoprolol in human plasma: comparison with an enantiospecific high-performance liquid chromatographic (HPLC) procedure. Pharm Res (1989) 0.76
Why monitor angiogenic factors in patients' urine? J Natl Cancer Inst (1994) 0.75
Penbutolol: pharmacokinetics, effect on exercise tachycardia, and in vitro inhibition of radioligand binding. Eur J Clin Pharmacol (1988) 0.75
Opioid-specific recognition sites of the mu- and the delta-type in rat striatum after lesions with kainic acid. Life Sci (1984) 0.75
Penbutolol: beta-adrenoceptor interaction and the time course of plasma concentrations explain its prolonged duration of action in man. Eur J Clin Pharmacol (1985) 0.75
[Decreased vagal tone in hyperkinetic heart syndrome?]. Z Kardiol (1990) 0.75
Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate. J Natl Cancer Inst (1993) 0.75
Correlation between pharmacological response, kinetics of plasma concentration and in vitro receptor affinities exemplified with beta-adrenoceptor blocking drugs. Methods Find Exp Clin Pharmacol (1984) 0.75
[Clinical and laboratory aspects of malignant hyperthermia in children with special reference to creatine kinase isoenzymes (author's transl)]. Anaesthesist (1978) 0.75
[Subtypes of muscarinic receptors--aspects of their physiologic significance for controlling heart rate in the human]. Z Kardiol (1994) 0.75
Increase of Bmax-values of beta-adrenoceptor sites after chronic treatment with reserpine? Pol J Pharmacol Pharm (1984) 0.75
[Creatine kinase isoenzyme MB and CK/GOT-ratio in the differential diagnosis of acute myocardial infarction (author's transl)]. Med Klin (1977) 0.75
[Serum creatinine determination using a simple kinetic technic at the Eppendorf enzyme measurement site 5080]. Med Lab (Stuttg) (1978) 0.75
AF-DX 116 discriminates heart from gland M2-cholinoceptors in man. Life Sci (1989) 0.75
[Correlation between pharmacokinetics and dynamics: explanation of clinical aspects exemplified by beta-receptor blockers]. Verh Dtsch Ges Inn Med (1991) 0.75
Heparin-binding growth factor blockade with pentosan polysulfate. Ann N Y Acad Sci (1993) 0.75
In vitro receptor occupancy allows to establish equieffective doses of beta-blockers with different pharmacodynamic profiles in man. Investigations with propranolol and bufuralol. Methods Find Exp Clin Pharmacol (1985) 0.75
Local control of mammary gland differentiation: mammary-derived growth inhibitor and pleiotrophin. Biochem Soc Symp (1998) 0.75
[Myocardial necrosis due to tocolysis with fenoterol (author's transl)]. J Gynecol Obstet Biol Reprod (Paris) (1979) 0.75
Beta-adrenoceptor sites in maturing red blood cells of the rat: differing development of agonist and antagonist binding. Eur J Pharmacol (1982) 0.75
AF-DX 116, a cardioselective muscarinic antagonist in humans: pharmacodynamic and pharmacokinetic properties. Clin Pharmacol Ther (1991) 0.75